• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Thursday's Intraday Session

    12/21/23 12:32:34 PM ET
    $ACON
    $ANEB
    $BEAT
    $CLNN
    Medical Specialities
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ACON alert in real time by email

    Gainers

    • HOOKIPA Pharma (NASDAQ:HOOK) stock moved upwards by 73.2% to $0.98 during Thursday's regular session. The market value of their outstanding shares is at $82.1 million.
    • HeartBeam (NASDAQ:BEAT) stock increased by 54.23% to $1.82. The market value of their outstanding shares is at $47.9 million.
    • PetVivo Hldgs (NASDAQ:PETV) shares moved upwards by 39.02% to $1.14. The market value of their outstanding shares is at $16.4 million.
    • OneMedNet (NASDAQ:ONMD) shares moved upwards by 37.5% to $1.1. The company's market cap stands at $35.4 million.
    • Anebulo Pharmaceuticals (NASDAQ:ANEB) stock moved upwards by 28.57% to $2.7. The company's market cap stands at $69.2 million.
    • MeiraGTx Hldgs (NASDAQ:MGTX) shares moved upwards by 27.89% to $6.28. The company's market cap stands at $399.3 million.

    Losers

    • Clene (NASDAQ:CLNN) stock fell 41.5% to $0.3 during Thursday's regular session. The market value of their outstanding shares is at $38.7 million.
    • Aclarion (NASDAQ:ACON) shares fell 28.06% to $0.25. The company's market cap stands at $2.3 million.
    • Panbela Therapeutics (NASDAQ:PBLA) shares decreased by 24.47% to $0.91. The company's market cap stands at $4.6 million.
    • Longeveron (NASDAQ:LGVN) stock decreased by 22.05% to $1.26. The market value of their outstanding shares is at $29.9 million.
    • Genetic Technologies (NASDAQ:GENE) stock fell 15.37% to $2.16. The market value of their outstanding shares is at $8.3 million.
    • Know Labs (AMEX:KNW) shares decreased by 13.51% to $0.51. The company's market cap stands at $41.5 million. As per the news, the Q4 earnings report came out 2 days ago. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $ACON alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ACON
    $ANEB
    $BEAT
    $CLNN

    CompanyDatePrice TargetRatingAnalyst
    Heartbeam Inc.
    $BEAT
    3/16/2026$8.00Buy → Speculative Buy
    The Benchmark Company
    Heartbeam Inc.
    $BEAT
    12/11/2025$8.00Speculative Buy → Buy
    The Benchmark Company
    Heartbeam Inc.
    $BEAT
    12/8/2025$2.50Buy
    H.C. Wainwright
    MeiraGTx Holdings plc
    $MGTX
    11/24/2025$20.00Buy
    H.C. Wainwright
    Heartbeam Inc.
    $BEAT
    10/31/2025$4.00Buy
    Roth Capital
    MeiraGTx Holdings plc
    $MGTX
    10/21/2025$29.00Strong Buy
    Raymond James
    HOOKIPA Pharma Inc.
    $HOOK
    12/20/2024$48.00 → $2.00Outperform → Sector Perform
    RBC Capital Mkts
    Longeveron Inc.
    $LGVN
    12/6/2024$10.00Buy
    ROTH MKM
    More analyst ratings

    $ACON
    $ANEB
    $BEAT
    $CLNN
    SEC Filings

    View All

    SEC Form 10-K filed by Aclarion Inc.

    10-K - Aclarion, Inc. (0001635077) (Filer)

    3/18/26 4:57:42 PM ET
    $ACON
    Medical Specialities
    Health Care

    SEC Form EFFECT filed by Heartbeam Inc.

    EFFECT - HeartBeam, Inc. (0001779372) (Filer)

    3/18/26 12:15:08 AM ET
    $BEAT
    Medical/Dental Instruments
    Health Care

    SEC Form 10-K filed by Longeveron Inc.

    10-K - Longeveron Inc. (0001721484) (Filer)

    3/17/26 4:01:02 PM ET
    $LGVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACON
    $ANEB
    $BEAT
    $CLNN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    HeartBeam downgraded by The Benchmark Company with a new price target

    The Benchmark Company downgraded HeartBeam from Buy to Speculative Buy and set a new price target of $8.00

    3/16/26 8:51:28 AM ET
    $BEAT
    Medical/Dental Instruments
    Health Care

    HeartBeam upgraded by The Benchmark Company with a new price target

    The Benchmark Company upgraded HeartBeam from Speculative Buy to Buy and set a new price target of $8.00

    12/11/25 8:45:10 AM ET
    $BEAT
    Medical/Dental Instruments
    Health Care

    H.C. Wainwright initiated coverage on HeartBeam with a new price target

    H.C. Wainwright initiated coverage of HeartBeam with a rating of Buy and set a new price target of $2.50

    12/8/25 8:34:44 AM ET
    $BEAT
    Medical/Dental Instruments
    Health Care

    $ACON
    $ANEB
    $BEAT
    $CLNN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    OneMedNet and Navidence Announce Strategic Collaboration: Empowering Pharma with Precision Real-World Data Insights

    MINNEAPOLIS, March 18, 2026 (GLOBE NEWSWIRE) -- OneMedNet Corporation (NASDAQ:ONMD) (the "OneMedNet," the "Company," "we," "us" or "our"), a leading provider of regulatory decision-grade, AI-ready Real-World Data (RWD), today announced a strategic collaboration with Navidence to help research organizations transform rapidly expanding healthcare data into clear, actionable real-world evidence. What This Collaboration Means for the Pharma Market Pharmaceutical companies face growing pressure to integrate high-quality RWD for regulatory submissions, post-market surveillance, and AI model training. Navidence's platform enables precise definition of health data needs via Computable Operationa

    3/18/26 8:50:00 AM ET
    $ONMD
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Longeveron Announces 2025 Full Year Financial Results and Provides Business Update

    On track for third quarter 2026 top-line trial results from anticipated pivotal Phase 2b clinical trial (ELPIS II) evaluating laromestrocel as a potential adjunct treatment for HLHS, a rare pediatric disease and orphan-designated indicationELPIS II may serve as foundation for a Biologics License Application (BLA) submission for full approval for HLHS, if results demonstrate sufficient evidence of efficacyClosed a private placement of up to $30 million, with $15 million funded in the initial closing, led by Coastlands Capital with participation from Janus Henderson Investors and other healthcare focused fundsCompany to host conference call and webcast today at 4:30 p.m. ET MIAMI, March 17

    3/17/26 4:05:00 PM ET
    $LGVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Aclarion to Participate in the 38th Annual ROTH Conference, Highlighting Key 2026 Catalysts and Strong Balance Sheet

    BROOMFIELD, Colo., March 17, 2026 (GLOBE NEWSWIRE) -- Aclarion, Inc., ("Aclarion" or the "Company") (NASDAQ:ACON, ACONW)), a commercial-stage healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, announced today that it will participate in the 38th Annual ROTH Conference, March 22-24, 2026, in Dana Point, CA. During the conference, CEO Brent Ness will engage in one-on-one meetings with institutional investors and analysts to discuss the company's progress advancing Nociscan, the company's proprietary MR spectroscopy platform designed to help physicians identify p

    3/17/26 6:00:00 AM ET
    $ACON
    Medical Specialities
    Health Care

    $ACON
    $ANEB
    $BEAT
    $CLNN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Willard Stephen H was granted 400,000 shares and covered exercise/tax liability with 105,533 shares (SEC Form 4)

    4 - Longeveron Inc. (0001721484) (Issuer)

    3/13/26 8:59:13 PM ET
    $LGVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    New insider Willard Stephen H claimed no ownership of stock in the company (SEC Form 3)

    3 - Longeveron Inc. (0001721484) (Issuer)

    3/13/26 8:58:57 PM ET
    $LGVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Large owner A.L. Sarroff Fund, Llc bought 1,250,000 shares (SEC Form 4)

    4 - PetVivo Holdings, Inc. (0001512922) (Issuer)

    3/13/26 5:10:25 PM ET
    $PETV
    Medical/Dental Instruments
    Health Care

    $ACON
    $ANEB
    $BEAT
    $CLNN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner A.L. Sarroff Fund, Llc bought 1,250,000 shares (SEC Form 4)

    4 - PetVivo Holdings, Inc. (0001512922) (Issuer)

    3/13/26 5:10:25 PM ET
    $PETV
    Medical/Dental Instruments
    Health Care

    Large owner A.L. Sarroff Fund, Llc converted options into 974,809 shares and bought $77,999 worth of shares (154,840 units at $0.50) (SEC Form 4)

    4 - PetVivo Holdings, Inc. (0001512922) (Issuer)

    1/16/26 4:38:39 PM ET
    $PETV
    Medical/Dental Instruments
    Health Care

    Large owner A.L. Sarroff Fund, Llc bought $485,355 worth of shares (718,358 units at $0.68) and converted options into 4,033,209 shares (SEC Form 4)

    4 - PetVivo Holdings, Inc. (0001512922) (Issuer)

    1/16/26 4:38:14 PM ET
    $PETV
    Medical/Dental Instruments
    Health Care

    $ACON
    $ANEB
    $BEAT
    $CLNN
    Leadership Updates

    Live Leadership Updates

    View All

    Longeveron® Appoints Stephen H. Willard as Chief Executive Officer

    Mr. Willard has a 30+ year track record of leadership across public and private sectors as CEO of multiple biotechnology and pharmaceutical firms, with an impressive history of delivering significant fundraises and strategic collaborationsCorporate focus on delivering top-line results from the pivotal Phase 2b clinical trial in Hypoplastic Left Heart Syndrome (HLHS), anticipated in the third quarter of 2026 Than Powell stepped down as interim CEO; will remain with the Company to support the leadership transition and continue his work in the Company's on-going business development activities MIAMI, Feb. 13, 2026 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ:LGVN), a clinical stage regenerati

    2/13/26 4:30:00 PM ET
    $LGVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    HeartBeam Appoints Bryan Humbarger as Chief Commercial Officer

    Brings more than 25 years of experience in building and scaling groundbreaking cardiovascular technologies Will initially focus on launching the Company's FDA-cleared 12-lead ECG system for arrhythmia assessment Will lead the Company's broader commercialization strategy across key growth initiatives, including heart attack detection and the 12-lead ECG extended-wear patch HeartBeam, Inc. (NASDAQ:BEAT), a medical technology company focused on transforming cardiac care by providing powerful cardiac insights, today announced the appointment of Bryan Humbarger as Chief Commercial Officer, effective January 22, 2026. In this newly created role, Mr. Humbarger will lead commercial strate

    1/22/26 7:00:00 AM ET
    $BEAT
    Medical/Dental Instruments
    Health Care

    Aclarion Appoints Jason Brosniak as Commercial Director to Drive Adoption and Market Expansion in the Eastern U.S.

    Proven commercial leader with 20+ years of experience driving revenue growth and market adoption for early-stage and high-growth MedTech companiesStrong track record of launching breakthrough technologies across spine, neurosurgery and pain managementStrengthens Aclarion's commercial execution as the Company expands adoption and payer engagement across the Eastern U.S. BROOMFIELD, Colo., Dec. 02, 2025 (GLOBE NEWSWIRE) -- Aclarion, Inc., ("Aclarion" or the "Company") (NASDAQ:ACON, ACONW)), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, today announced the

    12/2/25 8:00:00 AM ET
    $ACON
    Medical Specialities
    Health Care

    $ACON
    $ANEB
    $BEAT
    $CLNN
    Financials

    Live finance-specific insights

    View All

    Longeveron Announces 2025 Full Year Financial Results and Provides Business Update

    On track for third quarter 2026 top-line trial results from anticipated pivotal Phase 2b clinical trial (ELPIS II) evaluating laromestrocel as a potential adjunct treatment for HLHS, a rare pediatric disease and orphan-designated indicationELPIS II may serve as foundation for a Biologics License Application (BLA) submission for full approval for HLHS, if results demonstrate sufficient evidence of efficacyClosed a private placement of up to $30 million, with $15 million funded in the initial closing, led by Coastlands Capital with participation from Janus Henderson Investors and other healthcare focused fundsCompany to host conference call and webcast today at 4:30 p.m. ET MIAMI, March 17

    3/17/26 4:05:00 PM ET
    $LGVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    HeartBeam Reports Fourth Quarter and Full Year 2025 Results

    HeartBeam Enters New Growth Phase Following FDA Clearance for First-Ever, Cable-Free Synthesized 12-Lead ECG for At-Home Arrhythmia Assessment First Commercial Partner ClearCardio™ to Bring HeartBeam's 3D ECG Technology to High-Growth Preventive Cardiology Market First Patients Enrolled in Heart Attack Detection Pilot Study, A Key Step Toward Future FDA Indication Expansion Completed the First Working Prototype of an Extended-Wear 12-Lead ECG Patch Strategic Collaboration with the Icahn School of Medicine at Mount Sinai to Accelerate Next-Generation AI-ECG Algorithms Management to Host Webcast and Conference Call Today at 4:30 p.m. ET   HeartBeam, Inc. (NASDAQ:BEAT), a

    3/12/26 4:01:00 PM ET
    $BEAT
    Medical/Dental Instruments
    Health Care

    Longeveron to Report 2025 Full-Year Financial Results and Host Conference Call on March 17, 2026

    MIAMI, March 12, 2026 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ:LGVN), a clinical stage biotechnology company developing cellular therapy for life-threatening, rare pediatric and chronic aging-related conditions, today announced that it will report 2025 full year financial results and provide a business update on Tuesday, March 17, 2026 after the U.S. financial markets close. The Company will host a conference call and webcast the same day at 4:30 p.m. ET. Conference Call and Webcast Details: Conference Call Number:1.877.407.0789Conference ID:13758462  Call meTM Feature:Click HereWebcast:Click Here   An archived replay of the webcast will be available on the "Events & Presentations" sec

    3/12/26 9:00:00 AM ET
    $LGVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACON
    $ANEB
    $BEAT
    $CLNN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by PetVivo Holdings Inc.

    SC 13G/A - PetVivo Holdings, Inc. (0001512922) (Subject)

    11/19/24 3:38:53 PM ET
    $PETV
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by HOOKIPA Pharma Inc.

    SC 13G/A - HOOKIPA Pharma Inc. (0001760542) (Subject)

    11/14/24 6:07:08 PM ET
    $HOOK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Longeveron Inc.

    SC 13G/A - Longeveron Inc. (0001721484) (Subject)

    11/14/24 4:20:18 PM ET
    $LGVN
    Biotechnology: Pharmaceutical Preparations
    Health Care